SWS Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,573
| Closed | -$1.15M | – | 113 |
|
|
2026
Q1 | $1.15M | Buy |
2,573
+42
| +2% | +$19.6K | 0.28% | 86 |
|
|
2025
Q4 | $1.15M | Buy |
2,531
+13
| +0.5% | +$5.6K | 0.28% | 90 |
|
|
2025
Q3 | $986K | Buy |
2,518
+36
| +1% | +$15K | 0.24% | 96 |
|
|
2025
Q2 | $1.11M | Buy |
+2,482
| New | +$1.14M | 0.3% | 92 |
|
|
2025
Q1 | – | Sell |
-3,267
| Closed | -$1.32M | – | 117 |
|
|
2024
Q4 | $1.32M | Buy |
3,267
+20
| +0.6% | +$9.27K | 0.4% | 85 |
|
|
2024
Q3 | $1.51M | Sell |
3,247
-362
| -10% | -$174K | 0.48% | 76 |
|
|
2024
Q2 | $1.69M | Sell |
3,609
-737
| -17% | -$320K | 0.51% | 74 |
|
|
2024
Q1 | $1.82M | Sell |
4,346
-56
| -1% | -$23.7K | 0.54% | 73 |
|
|
2023
Q4 | $1.79M | Sell |
4,402
-72
| -2% | -$26.6K | 0.58% | 69 |
|
|
2023
Q3 | $1.56M | Sell |
4,474
-1,114
| -20% | -$390K | 0.58% | 70 |
|
|
2023
Q2 | $1.96M | Sell |
5,588
-60
| -1% | -$20.2K | 0.71% | 63 |
|
|
2023
Q1 | $1.78M | Buy |
+5,648
| New | +$1.69M | 0.66% | 69 |
|
|
2022
Q4 | – | Sell |
-5,592
| Closed | -$1.62M | – | 105 |
|
|
2022
Q3 | $1.62M | Buy |
5,592
+28
| +0.5% | +$8.06K | 0.75% | 60 |
|
|
2022
Q2 | $1.57M | Buy |
5,564
+11
| +0.2% | +$2.94K | 1.32% | 43 |
|
|
2022
Q1 | $1.45M | Sell |
5,553
-4,304
| -44% | -$1.02M | 0.95% | 58 |
|
|
2021
Q4 | $2.17M | Buy |
9,857
+2,508
| +34% | +$488K | 1.23% | 35 |
|
|
2021
Q3 | $1.33M | Buy |
7,349
+135
| +2% | +$26.4K | 0.83% | 64 |
|
|
2021
Q2 | $1.46M | Buy |
7,214
+140
| +2% | +$29.3K | 0.95% | 55 |
|
|
2021
Q1 | $1.52M | Buy |
7,074
+3,289
| +87% | +$722K | 1.05% | 48 |
|
|
2020
Q4 | $895K | Buy |
3,785
+1,030
| +37% | +$236K | 0.4% | 90 |
|
|
2020
Q3 | $750K | Buy |
2,755
+299
| +12% | +$82.5K | 0.38% | 79 |
|
|
2020
Q2 | $668K | Buy |
2,456
+261
| +12% | +$70.8K | 0.85% | 51 |
|
|
2020
Q1 | $522K | Buy |
+2,195
| New | +$504K | 0.37% | 75 |
|
|
2019
Q3 | $337K | Sell |
1,613
-178
| -10% | -$31.5K | 0.2% | 92 |
|
|
2019
Q2 | $319K | Buy |
+1,791
| New | +$313K | 0.2% | 94 |
|
|
2018
Q4 | $233K | Sell |
1,407
-132
| -9% | -$22.9K | 0.18% | 95 |
|
|
2018
Q3 | $297K | Buy |
+1,539
| New | +$274K | 0.19% | 86 |
|
Other funds holding VRTX
SWS Partners's VRTX Position: Q2 2026 in Review
SWS Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 2,573 shares — an estimated $1.15M sold.
SWS Partners first reported a position in VRTX in Q3 2018 and held it in 27 quarters. The position peaked at $2.17M in Q4 2021. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- SWS Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- SWS Partners sold 2,573 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.15M.
- SWS Partners first reported a position in Vertex Pharmaceuticals in Q3 2018 and held it in 27 quarters.
- SWS Partners's Vertex Pharmaceuticals position peaked at $2.17M in Q4 2021.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on SWS Partners's 13F filing for Q2 2026, filed 3 Aug 2026.